Orchard Therapeutics

Orchard Therapeutics, a Kyowa Kirin company, is a global leader in gene therapy focused on discovering, developing, and commercializing new treatments that harness the curative potential of hematopoietic stem cell gene therapy (HSC-GT). In this approach, a patient’s own blood stem cells are collected and genetically modified outside of the body and then re-infused, with the goal of correcting the underlying cause of disease in a single treatment.

Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC-GT. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, we carry forward our history of visionary science to imagine new possibilities for people and families affected by genetic and other severe diseases.

For more information, please visit www.orchard-tx.com. Healthcare providers requesting information on Orchard’s approved or investigational programs may contact medinfo@orchard-tx.com.